Eloralintide + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sleep Apnea, Obstructive
Conditions
Sleep Apnea, Obstructive, Obesity, Overweight
Trial Timeline
Feb 10, 2026 → Apr 1, 2028
NCT ID
NCT07369011About Eloralintide + Placebo
Eloralintide + Placebo is a phase 3 stage product being developed by Eli Lilly for Sleep Apnea, Obstructive. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07369011. Target conditions include Sleep Apnea, Obstructive, Obesity, Overweight.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07369011 | Phase 3 | Recruiting |
| NCT07392190 | Phase 3 | Recruiting |
| NCT07353931 | Phase 3 | Recruiting |
| NCT07321886 | Phase 3 | Recruiting |
| NCT07282600 | Phase 3 | Recruiting |
| NCT06916091 | Phase 1 | Completed |
Competing Products
20 competing products in Sleep Apnea, Obstructive